




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus



Fumihiko Yasui^a, Michinori Kohara^{a,*}, Masahiro Kitabatake^b, Tetsu Nishiwaki^c, Hideki Fujii^{d,h}, Chise Tateno^e, Misako Yoneda^f, Kouichi Morita^g, Kouji Matsushima^c, Shigeo Koyasu^{d,i}, Chieko Kai^f

^a Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan

^b Department of Immunology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan

^c Department of Molecular Preventive Medicine, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

^d Department of Microbiology and Immunology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

^e PhoenixBio Co., Ltd., 3-4-1 Kagamiyama, Higashihiroshima 739-0046, Japan

^f Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

^g Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

^h Department of Immunology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa 903-0213, Japan

ⁱ Laboratory for Immune Cell System, RCAI, RIKEN Research Center for Integrative Medical Sciences (IMS-RCAI), 1-7-22 Suehiro-cho, Yokohama 230-0045, Japan

ARTICLE INFO

Article history:

Received 28 November 2013

Returned to author for revisions

10 January 2014

Accepted 4 February 2014

Available online 4 March 2014

Keywords:

SARS-CoV

B cells

CD4⁺ T cells

Antibody

Phagocytic cells

Elimination

ABSTRACT

While the 2002–2003 outbreak of severe acute respiratory syndrome (SARS) resulted in 774 deaths, patients who were affected with mild pulmonary symptoms successfully recovered. The objective of the present work was to identify, using SARS coronavirus (SARS-CoV) mouse infection models, immune factors responsible for clearing of the virus. The elimination of pulmonary SARS-CoV infection required the activation of B cells by CD4⁺ T cells. Furthermore, passive immunization (post-infection) with homologous (murine) anti-SARS-CoV antiserum showed greater elimination efficacy against SARS-CoV than that with heterologous (rabbit) antiserum, despite the use of equivalent titers of neutralizing antibodies. This distinction was mediated by mouse phagocytic cells (monocyte-derived infiltrating macrophages and partially alveolar macrophages, but not neutrophils), as demonstrated both by adoptive transfer from donors and by immunological depletion of selected cell types. These results indicate that the cooperation of anti-SARS-CoV antibodies and phagocytic cells plays an important role in the elimination of SARS-CoV.

© 2014 Elsevier Inc. All rights reserved.

Introduction

From November 2002 to July 2003, the world suffered a global outbreak of severe acute respiratory syndrome (SARS). The disease, which resulted in 8098 cases with 774 deaths, was caused by a novel type of coronavirus, termed SARS-CoV, (http://www.who.int/csr/sars/country/table2004_04_21/en/index.html). Patients with SARS usually developed a high fever followed by clinical symptoms of lower respiratory tract disease. In severe cases, the patients presented with acute respiratory distress syndrome, characterized by diffuse alveolar damage, and ultimately died (Peiris et al., 2003a, 2003b; Fowler et al., 2003; Wang and Chang 2004). The hallmarks of severe cases of SARS included high viral titer, systemic infection, lymphopenia, and overproduction of proinflammatory cytokines/chemokines (often referred to as a “cytokine storm”) (Wong et al., 2004; Huang et al., 2005;

Cameron et al., 2007). However, there has been no subsequent consensus regarding which treatment, if any, benefited SARS patients during the outbreak (Stockman et al., 2007).

The development of an effective treatment strategy for SARS cases will require clarifying the precise mechanisms by which host immune responses control SARS-CoV infection. Cumulative evidence suggests that patients who recovered from SARS possessed specific acquired immunity based on both T and B cells (Yang et al., 2006, 2007; Li et al., 2008; Fan et al., 2009). However, the effector cells or molecules that act to eliminate SARS-CoV during the acute phase of the infection remain unclear. As the extensive outbreak of SARS has not recurred since 2003, the mechanisms by which SARS-CoV infection causes the pathogenesis and host immune responses has been investigated using adequate animal infectious models (Roberts et al., 2005, 2007; Nagata et al., 2008; Zhao et al., 2009; Zhao and Perlman, 2010). Lethal disease in BALB/c mice infected with a mouse-adapted strain of SARS-CoV, MA15, showed a lack of activation of innate immune response, resulting in a barely detectable antiviral T cell response (Zhao et al., 2009).

* Corresponding author. Tel.: +81 3 5316 3232; fax: +81 3 5316 3137.

E-mail address: kohara-mc@igakuken.or.jp (M. Kohara).

On the other hand, aged BALB/c mice that were infected with a human clinical isolate of SARS-CoV (Urbani strain) successfully eliminated the invasive virus within 1 week post-infection; these mice exhibited high and prolonged levels of viral replication, signs consistent with clinical symptoms, and pathologic changes in the lung resembling those seen in elderly SARS patients (Roberts et al., 2005). Therefore, the infection of these aged mice is considered a model for the successful elimination of SARS-CoV by host immune responses. A recent study reported that CD4⁺ T cells play an important role in the control of SARS-CoV infection (Chen et al., 2010). These researchers also reported an important role for innate defense mechanisms in controlling SARS-CoV infection, as demonstrated by the clearance of SARS-CoV over 9 days post-infection (dpi) in BALB/c mice depleted of both CD4⁺ and CD8⁺ T cells (Chen et al., 2010). These results suggest that both innate and adaptive immune responses are essential for controlling SARS-CoV infection. Nonetheless, the identity and role of effector cells and molecules participating in the elimination of SARS-CoV during the acute phase of SARS remain largely unknown.

In this study, we attempted to identify the types of immune cells that contribute to clearing SARS-CoV during the acute phase of the infection. This work employed several murine models in which hosts were deficient for (e.g., depleted via specific antibodies or lacking via immunodeficiency) or supplemented with (e.g., by adoptive transfer) individual immunologic effectors. We demonstrate that phagocytic cells (including monocyte-derived infiltrating macrophages and partially alveolar macrophages) play an important role in the elimination of SARS-CoV in mouse models of infection.

Results

Adaptive immune responses are essential for the elimination of pulmonary-infected SARS-CoV

As a first step, we confirmed the time course of viral titers in the lungs of aged (> 6 months old) BALB/c mice, young (7 weeks old) BALB/c mice, and young (8 weeks old) SCID mice following infection with SARS-CoV Vietnam/NB-04/2003. The intranasal (i.n.) infection of aged BALB/c mice with SARS-CoV resulted in over 10⁸ median tissue culture infectious dose (TCID₅₀)/g lung tissue at 2 dpi (Fig. 1A). The infected mice exhibited histological signs of severe pneumonia, including interstitial cell thickening, immune cell infiltration, and epithelial damage in the bronchus, at 9 dpi and 21 dpi (Fig. 1B(c and d)). These results were similar to those of the previous reports that used another SARS-CoV strain such as the Urbani strain (Roberts et al., 2005). In the present work, SARS-CoV was detected in aged mice starting as early as 2 dpi (Fig. 1A). The observed titers in the aged-mouse model were considerably higher than those seen in infected young BALB/c mice, which did not show apparent histological signs of pneumonia (Fig. 2B). Titers in the aged mice remained high (~10⁷ TCID₅₀/g lung tissue) at 6 dpi (Fig. 1A). However, the titers decreased to levels below the lower limit of detection (LLOD; < 1000 TCID₅₀/g lung tissue) in the lungs of aged BALB/c mice and young BALB/c mice at 9 dpi (Fig. 1A). In contrast, young SCID mice, which lack functional T and B cells, were persistently infected with SARS-CoV during the experimental period (through 21 dpi, as shown in Fig. 1A). At this time, SCID mice did not exhibit histological signs of severe pneumonia at 9 and 21 dpi, although a high viral titer was detected in the lungs of these animals during the experimental period (Fig. 1B(g and h) and C). Recently, Zhao and Perlman (2010) obtained similar results suggesting that a mouse-adapted mutant of SARS-CoV (viral strain MA15) persistently infected RAG1 knockout mice (C57BL/6 background),

animals that also lack T and B cell populations. Taken together, these results suggested that the pathogenesis of SARS does not correlate with the direct cytopathic effect of SARS-CoV. To investigate the effect of adaptive immune responses on clearance of pulmonary-infected SARS-CoV, either naïve splenocytes (obtained from BALB/c mice) or sensitized splenocytes (obtained from SARS-CoV-infected (9 dpi) BALB/c mice) were adoptively transplanted into naïve SCID mice 1 day before SARS-CoV infection. As shown in Fig. 1D, the SCID mice that received naïve splenocytes eliminated SARS-CoV from their lungs as early as the BALB/c mice did. The SCID mice transplanted with SARS-CoV-sensitized splenocytes of BALB/c mice eliminated SARS-CoV more rapidly than mice transplanted with naïve splenocytes, although the initial pulmonary viral titers were effectively the same in all groups of SCID mice at 2 dpi, with or without the transfer of splenocytes. Only one of the SCID mice that received sensitized splenocytes showed detectable lung pulmonary viral titer (3.5 × 10⁴ TCID₅₀/g lung) at 6 dpi; titers in the remaining 3 animals of this group (n=4/time point) were below the LLOD. The SCID mice transplanted with naïve- or sensitized-splenocytes derived from aged BALB/c mice did not show histological signs of severe pneumonia at 9 dpi, although infiltration of immunocompetent cells around bronchioles (arrows) was partially observed in the lung of both groups (Fig. 1E). These results indicated that induction of adaptive immune responses is essential for the clearance of pulmonary-infected SARS-CoV.

CD4⁺ T cells play an important role in the elimination of SARS-CoV-infected pulmonary cells, but this antiviral effect is indirect

To identify the host defense(s) involved in the elimination of SARS-CoV in the lung, we depleted CD4⁺ cells and/or CD8⁺ cells in BALB/c mice before and after SARS-CoV infection. Depletion of the CD4⁺ cells or CD8⁺ cells was performed by intravenous (i.v.) injection of (respectively) monoclonal antibody (mAb) GK1.5 or 53.6; control experiments demonstrated that injection of these mAbs produced virtually complete depletion of the corresponding cell populations (Fig. 1F). The CD4⁺ T cell-depleted BALB/c mice and the CD4⁺ T and CD8⁺ T cell-double-depleted BALB/c mice failed to eliminate the SARS-CoV-infected pulmonary cells by 9 dpi (Fig. 1G). In contrast, the CD8⁺ T cell-depleted BALB/c mice largely eliminated the SARS-CoV-infected pulmonary cells by 9 dpi (Fig. 1G). Recently, Chen et al. (2010) reported that both CD4⁺ T cells and neutralizing antibodies (following antibody response) play an important role in the elimination of SARS-CoV-infected pulmonary cells. However, it remains unclear whether the elimination of the virus in the present work and by Chen et al. (2010) reflects direct antiviral effect(s) by CD4⁺ T cells and/or B cells. Notably, several reports have demonstrated the presence of CD4⁺ T cells with cytotoxic activity during persistent viral infection, including infection by human immunodeficiency virus, human cytomegalovirus, and Epstein–Barr virus (Appay et al., 2002; Casazza et al., 2006; Landais et al., 2004). Furthermore, CD4⁺ T cell-mediated control of a γ -herpes virus in B cell-deficient mice is mediated by interferon-gamma (IFN- γ) (Christensen et al., 1999). In the present work, we found that SARS-CoV persistently infected the lung of nude (T cell-deficient) mice, as well as SCID mice (deficient of T cell and B cell), without inducing histological signs of pneumonia (Fig. 2A and B). Therefore, we investigated (using either of two models) whether CD4⁺ T cells could directly eliminate SARS-CoV via IFN- γ secretion. Our first model consisted of the adoptive transfer, 1 day before SARS-CoV infection, of CD4⁺ cells (1 × 10⁷ cells/mouse) from BALB/c mice into nude mice and SCID mice. The SCID mice that received the CD4⁺ T cell transfer did not eradicate SARS-CoV infection by 9 dpi (Fig. 2C). In contrast, nude mice that received the same quantity of CD4⁺ cells decreased the pulmonary viral titer below




Fig. 1. CD4⁺ T cells play an important role in the control of SARS-CoV infection. (A–C) aged BALB/c mice ($n=4-7$ /time point), young BALB/c mice ($n=5-10$ /time point), and young SCID mice ($n=4-8$ /time point) were infected intranasally with 1×10^5 TCID₅₀ of SARS-CoV Vietnam strain. (A) Virus titers in the lung (TCID₅₀/g lung tissue) of aged BALB/c mice (closed circles), young BALB/c mice (gray circles), or young SCID mice (open squares) sacrificed at 2, 4, 6, 9, or 21 dpi (except for 20 dpi in young BALB/c mice). * $p < 0.05$, ** $p < 0.01$ (compared with young BALB/c mice and SCID mice at the respective time point). N.D.: not detected. (B) Representative lung sections (hematoxylin and eosin staining; section thickness 4 μ m) from aged BALB/c mice at 9 dpi (a and c) and 21 dpi (b and d) and from young SCID mice at 9 dpi (e and g) and 21 dpi (f and h). For all micrographs, original magnification is 200 \times . (C) Detection of virus-infected cells in the lungs at 2, 9, or 21 dpi (SARS-CoV nucleocapsid protein [brown staining]; original magnification, 400 \times). (D) Temporal change of pulmonary virus titer in the following: aged BALB/c mice (green); untreated SCID mice (blue); SCID mice transplanted with splenocytes from naïve BALB/c mice (yellow); or SCID mice transplanted with splenocytes from sensitized BALB/c mice (red). Splenocytes (4×10^7 cells) were administered intravenously to each recipient SCID mouse 1 day before infection. Data are presented as mean \pm S.D. ($n=4$ /time point). * $p < 0.05$ (compared with naïve splenocyte-transplanted SCID mice at 2 dpi or with other groups at 4 dpi). (E) Representative lung sections (hematoxylin and eosin staining; section thickness 4 μ m) from each group in (D) at 9 dpi. SPL, splenocyte. For all micrographs, original magnification is 200 \times . (F) Flow cytometry analysis of CD4 and CD8 expression on lymphocytes isolated from spleen 1 day after administration of the indicated mAb. (G) Virus titers in the lung of untreated (white), CD8⁺ cell-depleted (light gray), CD4⁺ cell-depleted (dark gray), or CD4⁺ and CD8⁺ cell-depleted BALB/c mice (black) at 6 and 9 dpi. The limit of detection was $< 1 \times 10^3$ TCID₅₀/g lung. Data are presented as mean \pm S.D. ($n=3-7$ /time point).

the LLOD between 6 and 9 dpi (Fig. 2D). For our second model, we investigated the effect of IFN- γ on the elimination of SARS-CoV by using IFN- γ -deficient mouse models. The IFN- γ -deficient mice and the SCID mice that received splenocytes from IFN- γ deficient mice controlled the SARS-CoV infection as well as the wild-type mice did (Fig. 2E). These results demonstrated that CD4⁺ T cells are an essential cell type for the control of SARS-CoV infection, and that the effect of this cell fraction is indirect.

B cells and anti-SARS-CoV antibodies contribute to the control of SARS-CoV infection

The above results showed that SARS-CoV infection could be controlled both by nude mice which received CD4⁺ cells and by CD8⁺ cell-depleted BALB/c mice, suggesting that B cell is implicated in the elimination of SARS-CoV. So far, there are multiple studies that demonstrated the prophylactic effect of neutralizing antibodies against




Fig. 2. Antiviral effect of CD4⁺ cells is indirect. (A) Temporal change of virus titer in the lung of young BALB/c mice (closed circles) and young nude mice (open circles). Data are presented as mean \pm S.D. ($n=5$ /time point). N.D.: not detected. (B) Representative lung sections (hematoxylin and eosin staining; section thickness 4 μ m) from young BALB/c mice at 9 dpi (a) and 20 dpi (b) and young nude mice at 9 dpi (c) and 20 dpi (d). For all micrographs, original magnification is 200 \times . (C) Virus titer in the lung of CD4⁺ cell-transplanted SCID mice was determined at 6 and 9 dpi. Data are presented as mean \pm S.D. ($n=5$ /time point). CD4⁺ cells (1×10^7 cells) were administered to each recipient SCID mouse intravenously 1 day before challenge. (D) Virus titer in the lung of nude mice adoptively transplanted with CD4⁺ cells (gray) or residual cells (CD4⁻ cells; black), determined at 6 and 9 dpi. Untreated nude mice (white) were included as a control. CD4⁺ cells (1×10^7 cells) or residual cells (3×10^7 cells) were administered to each recipient nude mouse intravenously 1 day before challenge. Data are presented as mean \pm S.D. ($n=3$ /time point). (E) Pulmonary virus titer of IFN- γ deficient mice and splenocyte-transplanted SCID mice at 6 and 9 dpi. Splenocytes (4×10^7 cells) derived from IFN- γ deficient mice were administered to each recipient SCID mouse intravenously 1 day before challenge. Data are presented as mean \pm S.D. ($n=3$ /time point). N.D.: not detected. SPL, splenocyte.

SARS-CoV in animal models. (Casazza et al., 2006; Landais et al., 2004; Christensen et al., 1999; Nicholls et al., 2003; Lee et al., 2003; Peiris et al., 2004). Furthermore, we examined whether B cells play an important role in the elimination of SARS-CoV in the lung by using SCID mice that were transplanted with B cells of naïve BALB/c mice before infection with the virus. Although the CD19⁺ cell-transplanted SCID mice (CD19⁺ cells; purity 98.3%) did not decrease the pulmonary SARS-CoV titer by 9 dpi, the SCID mice that had received a combination of both cell fractions (the CD19⁺ cell subset and the residual cell subsets (CD19⁻ subsets containing T cells)) exhibited marked decreases in pulmonary SARS-CoV titer (to less than 1×10^4 TCID₅₀/g lung tissue; Fig. 3A). SCID mice that received the residual cell subsets alone (i.e., a CD19⁻ fraction) also did not exhibit decreased pulmonary SARS-CoV titer by 9 dpi (Fig. 3A).

To examine whether post-infection treatment with anti-SARS-CoV Abs could control SARS-CoV infection, SCID mice were infected i. n. with SARS-CoV and then were administered intraperitoneally (i.p.) twice with 0.5 mL of rabbit anti-spike (S) protein antiserum (neutralization titer [NT₅₀] > 300 against SARS-CoV; raised against SARS-CoV S protein expressed via recombinant vaccinia virus (Kitabatake et al., 2007; Yasui et al., 2008)). The group treated with anti-S protein antiserum eliminated SARS-CoV infection, but neither control group (treated with normal rabbit serum or rabbit antiserum raised against non-recombinant vaccinia virus) eliminated SARS-CoV infection

(Fig. 3B). The decrease of pulmonary-infected SARS-CoV titer in the anti-S protein antiserum-treated SCID mice was confirmed by quantitative RT-PCR for the detection of mRNA of the nucleocapsid (N) protein-encoding gene of SARS-CoV (Fig. 3C). These results suggested that the production of anti-SARS-CoV Abs by B cells, which is a T cell-dependent process, plays an important role in the control of SARS-CoV infection.

Neutralizing activity of antisera against SARS-CoV is not essential for the control of SARS-CoV infection

Multiple studies have demonstrated that neutralizing Abs are important humoral factors for the control of viral infection. As shown in Fig. 3B, administration of high-dose neutralizing Abs (NT₅₀ > 300; 0.5 mL \times 2 doses) eliminated SARS-CoV, although the antisera used were derived from other animal species. However, when BALB/c mice eradicated the SARS-CoV infection (9 dpi), the neutralization titer of antiserum from these BALB/c mice achieved an NT₅₀ of 40–80 (Yasui et al., 2008). To investigate whether the neutralizing activity of Abs is crucial for controlling SARS-CoV infection, the SARS-CoV-infected SCID mice were administered i.p. at 6 dpi with lower doses of either mouse anti-SARS-CoV antiserum or rabbit anti-S protein antiserum. For this experiment, the neutralization titers of both mouse anti-SARS-CoV antiserum and rabbit




Fig. 3. Clearance of SARS-CoV with anti-SARS-CoV antibodies does not correlate with neutralizing activity. (A) Virus titers in the lung of SCID mice adoptively transplanted with CD19⁺ cells (white), residual cells (CD19⁻ cells; gray), or both CD19⁺ and CD19⁻ cells (black) were determined at 6 and 9 dpi. CD19⁺ cells (2×10^7 cells) and/or residual cells (2×10^7 cells) were administered to each recipient SCID mouse intravenously 1 day before challenge. Data are presented as mean \pm S.D. ($n=3-4$ mice/time point). (B) Antiviral effect of post-infection administration of rabbit anti-S (spike) protein of SARS-CoV antibody (NT₅₀ > 300) (at 6 and 8 dpi) assessed as pulmonary virus titer at 9 dpi; untreated (white), normal rabbit serum-injected (gray), anti-vaccinia virus (VACV) antiserum (black), or anti-recombinant vaccinia virus expressing S protein of SARS-CoV (rVV-S) antiserum-injected (anti-S protein of SARS-CoV antiserum-injected). Data are presented as mean \pm S.D. ($n=5$ mice/time point). N.D.: not detected. (C) Quantitation of mRNA of nucleocapsid protein-encoding gene of SARS-CoV in the lung of SCID mice administered with anti-S protein antiserum. Total RNA extracted from the lungs was used to measure mRNA of nucleocapsid protein-encoding gene of SARS-CoV by quantitative RT-PCR. Each symbol indicates an individual subject. Heavy horizontal bars indicate the mean values for each treatment. * $p < 0.05$. (D) Antiviral effect of post-infection treatment with murine anti-SARS-CoV antiserum or rabbit anti-S (spike) protein of SARS-CoV antiserum at low neutralization titer in SCID mice infected with SARS-CoV. A single dose of antiserum (0.2 mL) was injected at 6 dpi at low (NT₅₀ = 13.3) or high (NT₅₀ = 40) neutralization titer. Two doses of antiserum (0.2 mL/dose) were injected at 6 and 8 dpi at high (NT₅₀ = 40) neutralization titer. The limit of detection was $< 1 \times 10^3$ TCID₅₀/g lung. Data are presented as mean \pm S.D. ($n=4$ mice/group). * $p < 0.05$. N.D.: not detected. (E) Relationship between pulmonary virus titer and neutralization titer against SARS-CoV in sera of SCID mice adoptively transplanted with murine anti-SARS-CoV antiserum or rabbit anti-S protein of SARS-CoV antiserum at 9 dpi; untreated group (open diamond), single dose of low-dose (NT₅₀ = 13.3, 0.2 mL; 6 dpi) murine anti-SARS-CoV antiserum (gray circle), single dose of high-dose (NT₅₀ = 40, 0.2 mL) murine anti-SARS-CoV antiserum (gray triangle), two doses of high-dose (NT₅₀ = 40, 0.2 mL \times 2; 6 and 8 dpi) murine anti-SARS-CoV antiserum (gray square), single dose of high-dose rabbit anti-S protein antiserum (closed triangle), two doses of high-dose rabbit anti-S protein antiserum (closed square). Note that symbol colors match classifications in panel (D).

anti-S protein antiserum were adjusted to $NT_{50}=40$; mouse anti-SARS-CoV antiserum also was tested at $NT_{50}=13.3$. As shown in Fig. 3D, the single injection (0.2 mL i.v., $NT_{50}=40$) of mouse SARS-CoV antiserum, but not that of rabbit anti-S protein antiserum, reduced the pulmonary SARS-CoV titer. The single injection of mouse anti-SARS-CoV antiserum at an even lower neutralization titer (0.2 mL, $NT_{50}=13.3$) also reduced the pulmonary virus titer by greater than 100-fold compared with that of untreated animals. Importantly, the SCID mice treated with rabbit anti-S protein antiserum did not eliminate SARS-CoV by 9 dpi, although the antisera of SCID mice treated with the rabbit antiserum clearly demonstrated neutralization activity against SARS-CoV (Fig. 3E). The inconsistency between the in vitro (neutralizing activity) and in vivo (clearance of pulmonary SARS-CoV) activities of the rabbit antiserum suggested that other effectors, besides anti-SARS-CoV Abs, also might be required to control SARS-CoV infection.

Phagocytic cells are essential for the elimination of the SARS-CoV-infected pulmonary cells in the presence of anti-SARS-CoV antibodies

To identify the effectors involved in the elimination of SARS-CoV-infected pulmonary cells in our mouse models, we tested the contribution of several candidate effectors. SARS-CoV-infected BALB/c mice were depleted of the first candidate, complement, by the injection of cobra venom factor (CVF; 40 U/mouse) at 5 and 6 dpi. Despite the depletion of C3 from the serum of BALB/c mice following CVF injection (Fig. 4A), CVF-treated BALB/c mice still eliminated SARS-CoV by 9 dpi (Fig. 4B). These results demonstrated that the complement-antibody complex is not required for the control of SARS-CoV infection in this model.

We next investigated the contribution of NK cells to the elimination of SARS-CoV by administering anti-IL-2R β mAb (TM- β 1), a treatment known to result in long-term depletion of NK cells (Tanaka et al., 1993). We injected i.p. TM- β 1 (100 μ L of ascites) into both SCID and BALB/c mice. Three days after TM- β 1 treatment, NK cell-depleted BALB/c mice splenocytes were transferred adoptively into NK cell-depleted SCID mice. The SCID mice were infected i.n. with SARS-CoV at 1 day after the splenocyte transfer. As shown in Fig. 4C, NK cells were considerably depleted in both the donor BALB/c mice (spleen) and the recipient SCID mice. However, virus still was eradicated in this NK-depleted model (Fig. 4D); thus, Ab-dependent cell-mediated cytotoxicity, which requires NK cells, was excluded as a mechanism for the elimination of SARS-CoV.

Other blood cells also may serve as effectors for the control of SARS-CoV. Specifically, elevated levels of alveolar macrophages, monocyte-derived infiltrating macrophages, and neutrophils were observed in many SARS patients (Nicholls et al., 2003; Lee et al., 2003). While these three cell types have been implicated in SARS pathology, the role of these cell subsets in the control of SARS-CoV infection is still unknown. To investigate the role of these myeloid cells in the clearance of SARS-CoV-infected pulmonary tissue, each subset of these myeloid cells was depleted by administration of a specific mAb or reagent. Consistent with previous reports (Pribul et al., 2008), alveolar macrophages were depleted for more than 5 days following i.n. administration of 100 μ L of 30% clodronate liposome (Fig. 5A). (Note that we used 30% clodronate liposome, thereby avoiding the intensive infiltration of neutrophils seen with administration of 100% clodronate liposome (Fig. 5A)). Neutrophils (CD11b⁺ and Ly-6G^{hi}) and Gr-1^{int} monocytes in blood and lung were significantly depleted for at least 3 days after i.p. treatment with 250 μ g of anti-Gr-1 mAb, whereas neutrophils alone were depleted upon administration of anti-Ly-6G mAb (1A8) (Fig. 5B and Daley et al., 2008). The Gr-1⁺ cell- and/or alveolar macrophage-depleted groups failed to eliminate the pulmonary SARS-CoV infection (Fig. 5C), whereas the alveolar macrophage-

depleted group showed partial elimination of the virus. In contrast, the neutrophil-depleted BALB/c animals (anti-Ly-6G mAb-treated mice) eliminated SARS-CoV by 9 dpi (Fig. 5C). Importantly, the neutralizing Ab titer of these cell-depleted mice was comparable to that of untreated BALB/c mice (Fig. 5D, $p=0.37$). Similar results were obtained in murine anti-SARS-CoV antisera-treated SCID mice that were administered with clodronate liposome and/or anti-Gr-1 mAb (Fig. 5E). These results suggest that phagocytic cells, especially monocyte-derived infiltrating macrophages, cooperate with anti-SARS-CoV Abs to provide control of SARS-CoV infection in these mouse models.

Discussion

The outbreak of SARS in 2002–2003 resulted in over 8000 cases, with 10% mortality. The worst symptoms might correlate with age-dependent defects of immune response, given that mortality exceeded 50% in patients over 65 years of age (Peiris et al., 2004). A recent study using MA15-infected mouse models suggested that age-dependent increases of prostaglandin D2 expression in the lung may be associated with impaired immune response (Zhao et al., 2011). Retrospective analyses of recovered SARS patients suggests that patients who recovered from SARS possessed specific acquired immunity based on both T and B cells (Yang et al., 2006, 2007; Li et al., 2008; Fan et al., 2009). Notably, most patients who recover from SARS had elevated and sustained levels of neutralizing Abs, and patients with longer illnesses exhibited lower levels of neutralizing Abs than did patients with shorter durations of illness (Temperton et al., 2005; Ho et al., 2005). Previous studies revealed that passive transfer of immune serum to naïve animals prevented SARS-CoV replication in the lower respiratory tract (Yang et al., 2004; Subbarao et al., 2004; Kam et al., 2007; Zhu et al., 2007; Rockx et al., 2008, 2011). Taken together, these results suggest that Ab responses likely play an important role in determining the ultimate disease outcome of SARS-CoV infection. Virus could be eradicated by direct binding of the virus by the neutralizing Abs and/or by cooperation between virus-specific Abs and other effector cells, including complement, NK cells, and phagocytic cells. However, the actual mechanism that controls the acute phase of SARS-CoV infection remained unclear.

In this study, we found that rabbit antiserum raised against the S protein of SARS-CoV exhibited significantly lower efficacy in the control of the virus infection than mouse anti-SARS-CoV antiserum when similar neutralization titers against SARS-CoV were transferred into recipient mice. Therefore, it appears that the neutralization activity of Ab against SARS-CoV does not correlate with the clearance efficacy of the virus from infected murine lung. On the other hand, some other antibody property (such as avidity) may differ between the murine and rabbit antisera, given that the former is a polyclonal species derived from SARS-CoV-infected mice, while the latter was generated in rabbit against the S protein. Further study will be needed to resolve this distinction. In a Chinese hamster model of SARS, post-infection treatment (at 1 dpi) with 100 mg/kg of equine neutralizing F(ab')₂ resulted in only partial reduction of pulmonary viral titer, although prophylactic treatment at a 10-fold lower dose was sufficient to completely block SARS-CoV infection (Luo et al., 2007). This result suggests that the anti-infective activity of a neutralizing Ab is mediated primarily via prevention of SARS-CoV invasion; the neutralizing Ab plays a lesser role in eliminating the virus after establishment of infection.

Therefore, we focused on the cooperation between anti-SARS-CoV Abs and other effectors in the control of SARS-CoV infection. Candidate effectors include complement (e.g., C3 and other




Fig. 4. Complement and NK cells are not required for the control of pulmonary-infected SARS-CoV. For panels (A) and (B), complement was depleted in BALB/c mice by administering cobra venom factor (CVF) intravenously at 5 dpi and 6 dpi; control animals were administered phosphate-buffered saline (PBS) by the same regimen. (A) Concentration of complement 3 in the sera of BALB/c mice was measured by ELISA. Data are presented as mean \pm S.D. ($n=4$ /time point). (B) Pulmonary virus titer of aged BALB/c mice treated with CVF (complement depletion), determined at 6 and 9 dpi. Data are presented as mean \pm S.D. ($n=4$ /group). N.D.: not detected. For panels (C) and (D), NK cells were depleted by administering anti-IL-2R β Ab (TM- β 1). Untreated BALB/c mice were used as controls. (C) Flow cytometric analysis of CD49b and TCR β expression of leukocytes in the spleen of BALB/c mice 3 days after the administration of TM- β 1 and in spleen and lung of SCID mice 4 days after the administration of TM- β 1. Representative diagrams are shown. (D) Splenocytes from BALB/c mice administered with TM- β 1 were adoptively transplanted into SCID mice that were previously administered with TM- β 1 to deplete NK cells. Pulmonary virus titers of BALB/c splenocyte-transplanted SCID mice were determined at 6 and 9 dpi. Data are presented as mean \pm S.D. ($n=3-4$ /group). N.D.: not detected.

members of the complement-antibody complex pathway), NK cells (mediators of the Ab-dependent cell-mediated cytotoxicity pathway), and Fc gamma receptor (Fc γ R)-bearing cells (notably alveolar macrophages, monocytes [monocytes-derived infiltrating macrophages], and neutrophils). A previous study reported that anti-Gr-1 mAb (RB6-8C5) recognizes not only neutrophils but also additional leukocyte populations, including monocytes (Daley et al., 2008). Therefore, we used both anti-Gr-1 mAb and neutrophil-specific mAb (anti-Ly-6G mAb) to discriminate monocytes and neutrophils. We tested the role of these candidates by selective depletion of a mouse infection model for various factors

using CVF (complement depletion), anti-IL-2R β mAb (TM- β 1; NK cell depletion), clodronate liposomes (alveolar macrophage depletion), anti-Gr-1 mAb (monocytes/neutrophil depletion), or anti-Ly6G mAb (neutrophil depletion) before or after SARS-CoV infection. Notably, the groups administered with clodronate liposome or anti-Gr-1 mAb, but not those treated with anti-Ly-6G mAb, failed to eliminate SARS-CoV from their lungs by 9 dpi. Our results indicated that phagocytic cells such as monocyte-derived infiltrating macrophages and partially alveolar macrophages, but not neutrophils, play a crucial role in the elimination of SARS-CoV-infected pulmonary cells in mice. Although little is known about




Fig. 5. Cooperation of phagocytic cells and antibodies is essential for the eradication of SARS-CoV infection. (A) Depletion of alveolar macrophages by intranasal administration of clodronate liposome. BALB/c mice were administered intranasally with 0.1 mL of 30% (left graph) or 100% clodronate liposome (right graph). Where applicable, dilution of clodronate liposome (to 30%) was performed using Dulbecco's PBS. Numbers of cells in bronchoalveolar lavage fluid (BALF) were determined by counting cell numbers (white, alveolar macrophages; black, other cells including neutrophils) following cytopsin preparation. Data are presented as mean ($n=2$ /time point). (B) Depletion of neutrophils and monocytes with anti-Gr-1 monoclonal antibody (mAb) or anti-Ly-6G mAb (respectively). The panel shows results of flow cytometric analysis of CD11b and Gr-1 expression of leukocytes in blood and lung of BALB/c mice at 3 days after the administration of anti-Gr-1 mAb or anti-Ly-6G mAb. Untreated BALB/c was used as a control. Representative diagrams are shown. (C) Pulmonary virus titers of BALB/c mice that were administered anti-Ly-6G mAb (depletion of neutrophils), clodronate liposome (depletion of alveolar macrophages; gray), anti-Gr-1 mAb (depletion of Gr-1⁺ cells; dark gray), or both clodronate liposome and anti-Gr-1 mAb (black) were determined 9 dpi. Data are presented as mean \pm S.D. ($n=3-7$ /group). N.D.: not detected. CL: clodronate liposome. (D) Neutralization titers against SARS-CoV in antisera of SARS-CoV-infected mice at 9 dpi. (E) Pulmonary virus titers of passively immunized SCID mice (i.e., injected with anti-SARS-CoV antiserum) that were administered clodronate liposome (CL; depletion of alveolar macrophages; gray), anti-Gr-1 mAb (depletion of Gr-1⁺ cells; dark gray), or both CL and anti-Gr-1 mAb (black) were determined at 9 dpi. Data are presented as mean \pm S.D. ($n=3-6$ /group). N.D.: not detected.

host defense mechanisms in the acute phase of SARS clinical infection, infiltration of large numbers of macrophages into the lungs of SARS patients was observed (Nicholls et al., 2003; Franks et al., 2003). Those reports are consistent with our results, although further studies are necessary to clarify the mechanism(s) of elimination of SARS-CoV via cooperation of phagocytic cells and SARS-CoV-specific antibodies.

While a previous study (Chen et al., 2010) and our results (Fig. 1G) showed that depletion of CD8⁺ T cell at the time of infection had little effect on viral replication or clearance, Zhao and Perlman (2010) reported that adoptive transfer of CD8⁺ T cells sensitized with the SARS-CoV MA 15 strain into naïve BALB/c mice completely protected the recipients from a subsequent challenge with lethal dose of MA15. Zhao et al. also showed that the diminished virus-specific CD8⁺ T cell responses resulted from inefficient activation of alveolar macrophages and respiratory dendritic cells in lethal diseases (Zhao et al., 2009, 2012; Zhao and Perlman, 2010). Their studies also demonstrated suboptimal responses of CD4⁺ T cell responses as well as CD8⁺ T cells, implying a critical role for antibody responsiveness in the MA15 infection model. In addition, while depletion of alveolar macrophages before MA15 infection completely protected mice from this lethal challenge, the depletion of alveolar macrophages at 2 days after MA15 infection appeared to exacerbate mortality (Zhao et al., 2009). Therefore, our findings would be rendered more persuasive by the inclusion of additional animal infection experiments using other patient isolates, such as the Urbani strain, and mouse-adapted strains, such as MA15, of SARS-CoV.

Although the importance of other effector cells for clearance of coronaviruses is still unknown, there are several reports that showed the implication of FcγR-bearing cells in the clearance of influenza virus. Fujisawa (2008) noted that neutrophils play a crucial role in the control of influenza virus infection by cooperation with anti-influenza virus antibodies. It also has been reported that FcRγ^{-/-} mice were highly susceptible to influenza virus infection, even in the presence of anti-influenza Abs from immune FcRγ^{+/+} mice (Huber et al., 2001). These results indicate the important role of FcγR-bearing effector cells in the clearance of influenza virus infections. In addition, we here demonstrated that both monocyte-derived macrophages (infiltrating-type) and partially alveolar macrophages (resident-type) contribute to the elimination of SARS-CoV-infected pulmonary cells in the presence of anti-SARS-CoV Abs.

Alveolar macrophages play a central role in maintaining lung homeostasis and are considered the first line of host defense against respiratory microbes. Marked enhancement of the virus titer was reported in other respiratory virus infection models (Pribul et al., 2008; Tumpey et al., 2005). On the other hand, monocytes circulate throughout the body in anticipation of inflammation and infection. Murine monocytes are reported to comprise two distinct subpopulations with different phenotypes: CX3CR1^{lo}CCR2⁺Gr-1⁺ and CX3CR1^{hi}CCR2⁻Gr-1⁻ monocytes (Geissmann et al., 2003). On infiltration of the infection site, Gr-1⁺ inflammatory monocytes can give rise to various dendritic cells and macrophage types (Varol et al., 2009). Iijima et al. (2011) demonstrated that Gr-1⁺ monocyte-derived APCs are required to elicit IFN-γ secretion from effector Th1 cells, thus mediating host protection against HSV-2 infection. Lin et al. (2008) reported that monocyte-derived DCs and macrophages cause immune pathology rather than viral clearance during influenza virus infection. In contrast, Gr-1⁺ monocyte-derived cells are involved in the clearance of SARS-CoV infection, although the role of Gr-1⁺ monocyte-derived cells in the development of pathogenesis during SARS-CoV infection remains unknown.

In conclusion, we demonstrate a crucial role for cooperation of antigen-specific antibodies and phagocytic cells (monocyte-derived

infiltrating macrophages and partially alveolar macrophages) in the elimination of SARS-CoV in mouse models of infection. Our findings provide a better understanding of the mechanism(s) by which host defenses control SARS-CoV infection. Ideally, this information can contribute to the development of novel therapeutic protocols or treatments for SARS.

Materials and methods

Virus and cells

These studies used the SARS-CoV Vietnam/NB-04/2003 strain. This strain, originally isolated from a single patient's throat lavage, was kindly provided by Dr. Mai Quynh Le (Hong et al., 2004) and further subcultured in Vero E6 cells grown in MEM (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan) containing 5% FCS. All work using SARS-CoV was performed in Biosafety Level 3 facilities by personnel wearing powered air-purifying respirators (Shigematsu Co., Ltd., Tokyo, Japan).

Mouse infection model

SCID mice (female, 7–8 weeks old) were purchased from CLEA Japan, Inc. (Tokyo, Japan). BALB/c mice (female, > 6 months old and 6–7 weeks old) and nude mice (female, 6 weeks old) were purchased from SLC (Shizuoka, Japan). The IFN-γ deficient mouse (BALB/c background) was the kind gift of Prof. Iwakura (The Institute of Medical Science, The University of Tokyo and Tokyo University of Science). On study day 0, mice were inoculated i.n. with SARS-CoV at 1×10^5 TCID₅₀ (20 μL) per mouse. At serial time points, mice were sacrificed under anesthesia following terminal blood collection, and the lungs were recovered. Portions of the tissues were frozen immediately at -80 °C or fixed in 10% buffered formalin. Blood was used for the in vitro neutralization assays and adoptive transfer experiments. All animal experiments using mice were approved by the Animal Experiment Committee at The Institute of Medical Science, The University of Tokyo, and were performed in accordance with the animal experimentation guidelines of The Institute of Medical Science, The University of Tokyo.

Depletion of immunocompetent cells

To confirm the depletion efficacy of anti-CD4 mAb (GK1.5; 100 μL of ascites) or anti-CD8 mAb (53.6; 100 μL of ascites), BALB/c mice were injected i.v. with the indicated dose volumes. At 1 day after administration of the respective mAb, spleen-derived lymphocytes were analyzed by flow cytometry for expression of CD4 and CD8. To test efficacy against SARS-CoV infection, the anti-CD4 mAb and/or anti-CD8 mAb was injected i.v. on days -3, 0, +3 and +6 with respect to the SARS-CoV challenge. For experiments examining the depletion of Gr-1⁺ (Ly-6G⁺ and Ly-6C⁺) cells, anti-Gr-1 mAb (250 μg, RB6-8C5; rat IgG2b) was injected i.p. 6 days after SARS-CoV challenge (Fujisawa, 2008). The hybridoma RB6-8C5 was obtained from the Cell Resource Center for Biomedical Research, Institute of Development, Aging, and Cancer, Tohoku University (Miyagi, Japan). Anti-IL2Rβ mAb (TM-β1), used for the depletion of NK cells (Tanaka et al., 1993), was the kind gift of Prof. Miyasaka (Osaka University, Japan). TM-β1 (100 μL of ascites) was injected i.p. 3 days before adoptive transfer of BALB/c mice splenocytes into both SCID and BALB/c mice. Anti-Ly6G mAb (1 mg, 1A8; rat IgG2a [purchased from Bio-XCell Co., Ltd.]) was injected i.p. 6 days after SARS-CoV challenge to deplete Ly-6G⁺ cells (neutrophils) (Daley et al., 2008). The depletion of the respective immunocompetent cells was confirmed by flow cytometric analysis. One hundred microliters of 30% clodronate liposome

suspension was injected i.n. in mice 6 days after SARS-CoV challenge to deplete alveolar macrophages (Pribul et al., 2008). The numbers of AMs were quantified in the bronchoalveolar lavage fluid (BALF). To deplete complement, cobra venom factor (CVF; 40 U/mouse, a gift of Prof. Okada, Nagoya City University, Japan) was injected i.p. in SCID mice both 5 and 6 days after SARS-CoV challenge (Pleyer et al., 1992).

Adoptive transfer of immunocompetent cells

Splenocytes were isolated from SARS-CoV-infected (9 dpi; sensitized) or naïve BALB/c mice (over 6 months old); the resulting cells then were administered (at 4×10^7 cells/animal) to recipient naïve SCID mouse i.v. 1 day before challenge. Splenocytes from NK cell-depleted BALB/c mice also were administered to recipient NK cell-depleted SCID mice as described above. CD4⁺ cells (1×10^7 cells) were isolated from the spleen of naïve BALB/c mice using anti-CD4 magnetic beads, followed by purification with an AutoMACS sorter (Miltenyi Biotech, Bergisch Gladbach, Germany). Isolated CD4⁺ cells (>96% purity) were adoptively transplanted into each recipient naïve SCID or nude mouse. In addition, splenocytes of naïve BALB/c mice were divided into the CD19⁺ cells (B cells) and residual cells (CD19⁻ cells, including T cells) using anti-CD19 magnetic beads (Miltenyi Biotech). The B cells (CD19⁺ cells; 2×10^7 cells/mouse) and/or the residual cells (CD19⁻ cells; 2×10^7 cells/mouse) then were adoptively transplanted into the recipient naïve SCID mice.

Passive transfer of antiserum

In our previous study, New Zealand White rabbits were immunized with a recombinant vaccinia virus LC16m8 strain expressing the gene for the S protein of SARS-CoV (Kitabatake et al., 2007). The resulting antisera (rabbit anti-S protein) showed high neutralizing activity against SARS-CoV ($NT_{50} > 300$). As negative controls for this rabbit anti-S antiserum, we used normal rabbit serum and/or rabbit antiserum against vaccinia virus strain LC16m8. Mouse anti-SARS-CoV antiserum was obtained from BALB/c mice at 9 days after SARS-CoV infection, at which point the antiserum exhibited $NT_{50} = \sim 40$. For passive transfer, each recipient naïve mouse received 0.2–0.5 mL of rabbit anti-S protein antiserum or mouse anti-SARS-CoV antiserum, administered i.v. at 6 dpi (or at 6 and 8 dpi).

Determination of viral titers in the lung

The SARS-CoV titers in the murine lung were determined as described previously (Yasui et al., 2008). Briefly, lung tissue samples were homogenized in 10 volumes of Leibovitz 15 medium (Invitrogen, CA, USA). The homogenate was centrifuged at $400 \times g$ for 10 min at 4 °C. The supernatant was collected and stored at –80 °C until use. Serial 10-fold dilutions of the supernatant were added to Vero E6 cells seeded on 96-well plates. After 6 days of incubation, the cells were fixed with 10% buffered formalin. Viral titers were determined as the 50% endpoint dilution of the homogenate that induced the cytopathic effect, and were expressed as $TCID_{50}$ per gram of tissue. The method used for endpoint calculation was that described by Reed and Muench (1938).

In vitro neutralization assay for SARS-CoV

Serial 2-fold dilutions of heat-inactivated sera (>1:4) were mixed with equal volumes of 200 $TCID_{50}$ of SARS-CoV and incubated at 37 °C for 1 h. Vero E6 cells then were infected with 100 μ L of the virus-serum mixtures in 96-well plates. After 6 days of incubation, the neutralization titer was determined as the endpoint dilution of the serum at which there was 50% inhibition

of the SARS-CoV-induced cytopathic effect. The method used for endpoint calculation was that described by Reed and Muench (1938).

Lung histopathology and immunohistochemistry

In accordance with a previous report, 10% formalin-fixed lung tissues of the SARS-CoV-infected mice were embedded in paraffin (Yasui et al., 2008). Paraffin block sections (4- μ m thickness) were stained with hematoxylin and eosin. Antigen retrieval was performed by autoclaving sections in 10 mM citrate buffer (pH 6.0) for 20 min, and then the sections were immersed in 3% hydrogen peroxide (H_2O_2) at room temperature (RT) for 5 min to inactivate endogenous peroxidase. The sections were blocked with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 at RT for 30 min, and then were incubated (overnight at 4 °C) with 1 μ g/mL of anti-N protein of SARS-CoV polyclonal antibody (pAb) (IMG548; IMGENEX, San Diego, CA, USA). Secondary labeling was performed by incubation (at RT for 2 h) with 1:1000 donkey anti-rabbit IgG (GE Healthcare, Buckinghamshire, UK), followed by color development with 3,3'-diaminobenzidine in 50 mM Tris-HCl (pH 7.6) for 30 min. Nuclear staining was performed with hematoxylin solution. Slides were imaged using an Axio Imager A2 microscope (Carl Zeiss Inc., Oberkochen, Germany).

Extraction of total RNA and quantitative RT-PCR

Total RNA samples were extracted from lung using the Illustra RNAspin Midi isolation kit (GE Healthcare) according to the manufacturer's instructions. Messenger RNA levels for the N protein-encoding gene of SARS-CoV were measured using the TaqMan EZ RT-PCT kit (Applied Biosystems, Branchburg, NJ, USA). Each 25 μ L reaction mixture contained 5.0 μ L $5 \times$ TaqMan EZ buffer, 3.0 μ L 25 mM Mn(OAc)₂, 0.25 μ L 1 U/ μ L AmpErase UNG (uracil N-glycosylase), 1.0 μ L 2.5 U/ μ L of rTth DNA polymerase, 3.0 μ L dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM dGTP, and 20 mM dUTP), 0.25 μ L 10 μ M probe, 0.25 μ L each 50 μ M forward and reverse primers, 7.0 μ L nuclease-free water, and 5.0 μ L nucleic acid extract. Amplification was carried out in 96-well plates on the ABI Prism 7700 and Sequence Detection System software ver. 1.7. Thermocycling conditions consisted of 2 min at 50 °C for UNG treatment, 30 min at 60 °C for reverse transcription, 5 min at 95 °C for deactivation of UNG, and 50 cycles of 15 s at 95 °C and 1 min at 60 °C for amplification. Each run included pEFMyc-His-SARS-N plasmid (at 10^1 , 10^2 , 10^3 , 10^4 , 10^6 , and 10^8 copies/5 μ L) to provide a standard curve and at least one no-template control. The primers and probe used in this study were as follows: forward primer, 5'-GGAGCCTTGAATACACCCAAAG-3'; reverse primer, 5'-GCACGG-TGGCAGCATTG-3'; probe, 5'-(FAM)-CCACATTGGCACCCGAATCC-(TAMRA)-3'.

Quantitation of complement C3 serum level

The depletion of complement was quantified by enzyme-linked immunosorbent assay (ELISA) for mouse complement C3 (Kamiya Biomedical Company, Seattle, WA, USA).

Statistical analysis

Data are presented as mean \pm standard deviation (SD), where applicable. Inferential statistical analysis was performed by One-Way ANOVA, followed by Tukey's test. Non-parametric analysis was performed using the Kruskal–Wallis test, followed by Mann–Whitney's *U* test. A *p* value < 0.05 was considered statistically significant. All statistical calculations were performed with SPSS Statistics 17.0 software (SPSS Inc., Chicago, IL, USA).

Acknowledgments

We express our gratitude to Ms. Iyo Kataoka of the Institute of Medical Science, The University of Tokyo, for technical assistance in the evaluation of lung histopathology.

This study was supported in part by JSPS KAKENHI Grant number 21790455, the 21st Century Centers of Excellence (COE) Program on Global Strategies for Control of Tropical and Emerging Infectious Diseases at Nagasaki University, and by the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References

- Appay, V., Saunders, J.J., Papagno, L., Sutton, J., Jaramillo, A., Waters, A., Easterbrook, P., Grey, P., Smith, D., McMichael, A.J., Cooper, D.A., Rowland-Jones, S.L., Kelleher, A.D., 2002. Characterization of CD4⁺ CTLs ex vivo. *J. Immunol.* 168, 5954–5958.
- Cameron, M.J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J.F., Cameron, C.M., Muller, M.P., Gold, W.L., Richardson, S.E., Poutanen, S.M., Willey, B.M., DeVries, M.E., Fang, Y., Seneviratne, C., Bosinger, S.E., Persad, D., Wilkinson, P., Greller, L. D., Somogyi, R., Humar, A., Keshavjee, S., Louie, M., Loeb, M.B., Brunton, J., McGeer, A.J., Kelvin, D.J., 2007. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. *J. Virol.* 81, 8692–8706.
- Casazza, J.P., Betts, M.R., Price, D.A., Precopio, M.L., Ruff, L.E., Brenchley, J.M., Hill, B.J., Roederer, M., Douek, D.C., Koup, R.A., 2006. Acquisition of direct antiviral effector functions by CMV-specific CD4⁺ T lymphocytes with cellular maturation. *J. Exp. Med.* 203, 2865–2877.
- Chen, J., Lau, Y.F., Lamirande, E.W., Paddock, C.D., Bartlett, J.H., Zaki, S.R., Subbarao, K., 2010. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4⁺ T cells are important in control of SARS-CoV infection. *J. Virol.* 84, 1289–1301.
- Christensen, J.P., Cardin, R.D., Branum, K.C., Doherty, P.C., 1999. CD4⁺ T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. *Proc. Natl. Acad. Sci. USA* 96, 5135–5140.
- Daley, J.M., Thomay, A.A., Connolly, M.D., Reichner, J.S., Albina, J.E., 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. *J. Leukoc. Biol.* 83, 64–70.
- Fan, Y.Y., Huang, Z.T., Li, L., Wu, M.H., Yu, T., Koup, R.A., Bailer, R.T., Wu, C.Y., 2009. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. *Arch. Virol.* 154, 1093–1099.
- Fowler, R.A., Lapinsky, S.E., Hallett, D., Detsky, A.S., Sibbald, W.J., Slutsky, A.S., Stewart, T.E., 2003. Critically ill patients with severe acute respiratory syndrome. *J. Am. Med. Assoc.* 290, 367–373.
- Franks, T.J., Chong, P.Y., Chui, P., Galvin, J.R., Lourens, R.M., Reid, A.H., Selbs, E., McEvoy, C.P., Hayden, C.D., Fukuoka, J., Taubenberger, J.K., Travis, W.D., 2003. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. *Hum. Pathol.* 34, 743–748.
- Fujisawa, H., 2008. Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. *J. Virol.* 82, 2772–2783.
- Geissmann, F., Jung, S., Littman, D.R., 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity* 19, 71–82.
- Ho, M.S., Chen, W.J., Chen, H.Y., Lin, S.F., Wang, M.C., Di, J., Lu, Y.T., Liu, C.L., Chang, S. C., Chao, C.L., King, C.C., Chiou, J.M., Su, I.J., Yang, J.Y., 2005. Neutralizing antibody response and SARS severity. *Emerg. Infect. Dis.* 11, 1730–1737.
- Hong, T.C., Mai, Q.L., Cuong, D.V., Parida, M., Minekawa, H., Notomi, T., Hasebe, F., Morita, K., 2004. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. *J. Clin. Microbiol.* 42, 1956–1961.
- Huang, K.J., Su, I.J., Theron, M., Wu, Y.C., Lai, S.K., Liu, C.C., Lei, H.Y., 2005. An interferon-gamma-related cytokine storm in SARS patients. *J. Med. Virol.* 75, 185–194.
- Huber, V.C., Lynch, J.M., Bucher, D.J., Le, J., Metzger, D.W., 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. *J. Immunol.* 166, 7381–7388.
- Iijima, N., Mattei, L.M., Iwasaki, A., 2011. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. *Proc. Natl. Acad. Sci. USA* 108, 284–289.
- Kam, Y.W., Kien, F., Roberts, A., Cheung, Y.C., Lamirande, E.W., Vogel, L., Chu, S.L., Tse, J., Guarner, J., Zaki, S.R., Subbarao, K., Peiris, M., Nal, B., Altmeyer, R., 2007. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc-gammaRII-dependent entry into B cells in vitro. *Vaccine* 25, 729–740.
- Kitabatake, M., Inoue, S., Yasui, F., Yokochi, S., Arai, M., Morita, K., Shida, H., Kidokoro, M., Murai, F., Le, M.Q., Mizuno, K., Matsushima, K., Kohara, M., 2007. SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. *Vaccine* 25, 630–637.
- Landais, E., Saulquin, X., Scotet, E., Trautmann, L., Peyrat, M.A., Yates, J.L., Kwok, W. W., Bonneville, M., Houssaint, E., 2004. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. *Blood* 103, 1408–1416.
- Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G.M., Ajuja, A., Yung, M.Y., Leung, C.B., To, K.F., Lui, S.F., Szeto, C.C., Chung, S., Sung, J.J., 2003. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.* 348, 1986–1994.
- Li, C.K., Wu, H., Yan, H., Ma, S., Wang, L., Zhang, M., Tang, X., Temperton, N.J., Weiss, R.A., Brenchley, J.M., Douek, D.C., Mongkolsapaya, J., Tran, B.H., Lin, C.L., Screaton, G.R., Hou, J.L., McMichael, A.J., Xu, X.N., 2008. T cell responses to whole SARS coronavirus in humans. *J. Immunol.* 181, 5490–5500.
- Lin, K.L., Suzuki, Y., Nakano, H., Ramsburg, E., Gunn, M.D., 2008. CCR2⁺ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. *J. Immunol.* 180, 2562–2572.
- Luo, D., Ni, B., Zhao, G., Jia, Z., Zhou, L., Pacal, M., Zhang, L., Zhang, S., Xing, L., Lin, Z., Wang, L., Li, J., Liang, Y., Shi, X., Zhao, T., Zou, L., Wu, Y., Wang, X., 2007. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')₂. *Vir. Immunol.* 20, 495–502.
- Nagata, N., Iwata, N., Hasegawa, H., Fukushi, S., Harashima, A., Sato, Y., Saijo, M., Taguchi, F., Morikawa, S., Sata, T., 2008. Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. *Am. J. Pathol.* 172, 1625–1637.
- Nicholls, J.M., Poon, L.L., Lee, K.C., Ng, W.F., Lai, S.T., Leung, C.Y., Chu, C.M., Hui, P.K., Mak, K.L., Lim, W., Yan, K.W., Chan, K.H., Tsang, N.C., Guan, Y., Yuen, K.Y., Peiris, J.S., 2003. Lung pathology of fatal severe acute respiratory syndrome. *Lancet* 361, 1773–1778.
- Peiris, J.S., Chu, C.M., Cheng, V.C., Chan, K.S., Hung, I.F., Poon, L.L., Law, K.I., Tang, B.S., Hon, T.Y., Chan, C.S., Chan, K.H., Ng, J.S., Zheng, B.J., Ng, W.L., Lai, R.W., Guan, Y., Yuen, K.Y., 2003a. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* 361, 1767–1772.
- Peiris, J.S., Yuen, K.Y., Osterhaus, A.D., Stohr, K., 2003b. The severe acute respiratory syndrome. *N. Engl. J. Med.* 349, 2431–2441.
- Peiris, J.S., Guan, Y., Yuen, K.Y., 2004. Severe acute respiratory syndrome. *Nat. Med.* 10, S88–S97.
- Pleyer, U., Mondino, B.J., Sumner, H.L., 1992. The effect of systemic decompensation with cobra venom factor on corneal complement levels in guinea pigs. *Invest. Ophthalmol. Vis. Sci.* 33, 2212–2215.
- Pribul, P.K., Harker, J., Wang, B., Wang, H., Tregoning, J.S., Schwarze, J., Openshaw, P. J., 2008. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. *J. Virol.* 82, 4441–4448.
- Reed, L.J., Muench, H., 1938. A simple method of estimating fifty percent endpoints. *Am. J. Hyg.* 27, 493–497.
- Roberts, A., Paddock, C., Vogel, L., Butler, E., Zaki, S., Subbarao, K., 2005. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. *J. Virol.* 79, 5833–5838.
- Roberts, A., Deming, D., Paddock, C.D., Cheng, A., Yount, B., Vogel, L., Herman, B.D., Sheahan, T., Heise, M., Genrich, G.L., Zaki, S.R., Baric, R., Subbarao, K., 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. *PLoS Pathog.* 3, e5.
- Rockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., Baric, R., 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. *J. Virol.* 82, 3220–3235.
- Rockx, B., Donaldson, E., Frieman, M., Sheahan, T., Corti, D., Lanzavecchia, A., Baric, R.S., 2011. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. *J. Infect. Dis.* 201, 946–955.
- Stockman, L.J., Massoudi, M.S., Helfand, R., Erdman, D., Siwek, A.M., Anderson, L.J., Parashar, U.D., 2007. Severe acute respiratory syndrome in children. *Pediatr. Infect. Dis. J.* 26, 68–74.
- Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W.J., Zaki, S., Murphy, B., 2004. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *J. Virol.* 78, 3572–3577.
- Tanaka, T., Kitamura, F., Nagasaka, Y., Kuida, K., Suwa, H., Miyasaka, M., 1993. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. *J. Exp. Med.* 178, 1103–1107.
- Temperton, N.J., Chan, P.K., Simmons, G., Zambon, M.C., Tedder, R.S., Takeuchi, Y., Weiss, R.A., 2005. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. *Emerg. Infect. Dis.* 11, 411–416.
- Tumpey, T.M., Garcia-Sastre, A., Taubenberger, J.K., Palese, P., Swaney, D.E., Pantin-Jackwood, M.J., Schultz-Cherry, S., Solorzano, A., Van Rooijen, N., Katz, J.M., Basler, C.F., 2005. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. *J. Virol.* 79, 14933–14944.
- Varol, C., Yona, S., Jung, S., 2009. Origins and tissue-context-dependent fates of blood monocytes. *Immunol. Cell Biol.* 87, 30–38.
- Wang, J.T., Chang, S.C., 2004. Severe acute respiratory syndrome. *Curr. Opin. Infect. Dis.* 17, 143–148.
- Wong, C.K., Lam, C.W., Wu, A.K., Ip, W.K., Lee, N.L., Chan, I.H., Lit, L.C., Hui, D.S., Chan, M.H., Chung, S.S., Sung, J.J., 2004. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin. Exp. Immunol.* 136, 95–103.
- Yang, L., Peng, H., Zhu, Z., Li, G., Huang, Z., Zhao, Z., Koup, R.A., Bailer, R.T., Wu, C., 2007. Persistent memory CD4⁺ and CD8⁺ T-cell responses in recovered severe

- acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. *J. Gen. Virol.* 88, 2740–2748.
- Yang, L.T., Peng, H., Zhu, Z.L., Li, G., Huang, Z.T., Zhao, Z.X., Koup, R.A., Bailer, R.T., Wu, C.Y., 2006. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. *Clin. Immunol.* 120, 171–178.
- Yang, Z.Y., Kong, W.P., Huang, Y., Roberts, A., Murphy, B.R., Subbarao, K., Nabel, G.J., 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 428, 561–564.
- Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., Suzuki, H., Karamatsu, K., Yasutomi, Y., Shida, H., Kidokoro, M., Mizuno, K., Matsushima, K., Kohara, M., 2008. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. *J. Immunol.* 181, 6337–6348.
- Zhao, J., Perlman, S., 2010. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J. Virol.* 84, 9318–9325.
- Zhao, J., Van Rooijen, N., Perlman, S., 2009. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. *PLoS Pathog.* 5, e1000636.
- Zhao, J., Zhao, J., Legge, K., Perlman, S., 2011. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. *J. Clin. Invest.* 121, 4921–4930.
- Zhao, J., Wohlford-Lenane, C., Zhao, J., Fleming, E., Lane, T.E., McCray, P.B., Perlman, S., 2012. Intranasal treatment with poly(I-C) protects aged mice from lethal respiratory virus infections. *J. Virol.* 86, 11416–11424.
- Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L.E., Prabakaran, P., Rockx, B., Sidorov, I.A., Corti, D., Vogel, L., Feng, Y., Kim, J.O., Wang, L.F., Baric, R., Lanzavecchia, A., Curtis, K.M., Nabel, G.J., Subbarao, K., Jiang, S., Dimitrov, D.S., 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. *Proc. Natl. Acad. Sci. USA* 104, 12123–12128.